NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Price, News & Analysis $2.24 +0.05 (+2.28%) (As of 05:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Esperion Therapeutics Stock (NASDAQ:ESPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Esperion Therapeutics alerts:Sign Up Key Stats Today's Range$2.19▼$2.2950-Day Range$2.00▼$3.8352-Week Range$1.58▼$3.94Volume2.80 million shsAverage Volume6.36 million shsMarket Capitalization$441.36 millionP/E RatioN/ADividend YieldN/APrice Target$7.30Consensus RatingHold Company OverviewEsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Read More… Esperion Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks79th Percentile Overall ScoreESPR MarketRank™: Esperion Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 216th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingEsperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Esperion Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.27) to $0.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.63% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Esperion Therapeutics has recently decreased by 2.43%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.76 Percentage of Shares Shorted15.63% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Esperion Therapeutics has recently decreased by 2.43%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment0.57 News SentimentEsperion Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Esperion Therapeutics this week, compared to 4 articles on an average week.Search Interest34 people have searched for ESPR on MarketBeat in the last 30 days. This is an increase of 127% compared to the previous 30 days.MarketBeat Follows14 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $227.00 in company stock.Percentage Held by InsidersOnly 1.00% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Esperion Therapeutics' insider trading history. Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Stock News HeadlinesAnalysts Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $8.13December 23 at 4:09 AM | americanbankingnews.comCantor Fitzgerald Comments on ESPR FY2024 EarningsDecember 21 at 2:08 AM | americanbankingnews.comCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.December 23, 2024 | ProsperityPub (Ad)3 High-Growth Biotech Stocks to WatchDecember 19, 2024 | stocknews.comPaul Choi Assigns Hold Rating to Esperion Due to Market Uncertainty and Pipeline ChallengesDecember 19, 2024 | markets.businessinsider.comEsperion closes refinancing transactionsDecember 19, 2024 | markets.businessinsider.comEsperion Strengthens Balance Sheet with Closing of Significant Refinancing TransactionsDecember 18, 2024 | globenewswire.comCantor Fitzgerald Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight RecommendationDecember 17, 2024 | msn.comSee More Headlines ESPR Stock Analysis - Frequently Asked Questions How have ESPR shares performed this year? Esperion Therapeutics' stock was trading at $2.99 on January 1st, 2024. Since then, ESPR shares have decreased by 25.1% and is now trading at $2.24. View the best growth stocks for 2024 here. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) issued its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.03. The biopharmaceutical company had revenue of $32.25 million for the quarter, compared to analysts' expectations of $26.84 million. Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' top institutional investors include Wasatch Advisors LP (11.85%), Geode Capital Management LLC (2.20%), State Street Corp (1.96%) and Parkman Healthcare Partners LLC (0.46%). Insiders that own company stock include Sheldon L Koenig, Eric Warren, Joanne M Foody, Benjamin Looker and J Martin Carroll. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Esperion Therapeutics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and AUO (AUOTY). Company Calendar Last Earnings2/27/2024Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ESPR CUSIPN/A CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Stock Price Target$7.30 High Stock Price Target$16.00 Low Stock Price Target$2.50 Potential Upside/Downside+230.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,250,000.00 Net Margins-29.37% Pretax Margin-29.37% Return on EquityN/A Return on Assets-10.77% Debt Debt-to-Equity RatioN/A Current Ratio1.85 Quick Ratio1.37 Sales & Book Value Annual Sales$295.45 million Price / Sales1.47 Cash FlowN/A Price / Cash FlowN/A Book Value($3.85) per share Price / Book-0.57Miscellaneous Outstanding Shares197,035,000Free Float195,065,000Market Cap$435.45 million OptionableOptionable Beta1.01 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ESPR) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.